Syngene shares jump 17% after Q4 results; check Macquarie price target
Published on 30/04/2026 01:44 PM
Syngene shares jump 17% after Q4 results; check Macquarie price targetRevenue continues to be impacted by lower business from a single large molecule biologics client. Excluding this, the underlying business showed steady momentum.By CNBCTV18.com April 30, 2026, 1:44:42 PM IST (Updated)1 Min ReadShares of Syngene International Ltd. surged as much as 17% on Thursday, April 30, after the company reported its Q4FY26 earnings.
Revenue for the quarter rose 1.8% year-on-year to ₹1,037 crore from ₹1,018 crore. However, profitability remained under pressure, with net profit declining 19.3% YoY to ₹147.9 crore.
EBITDA fell 11.7% to ₹303.4 crore from ₹343.6 crore in the year-ago period, leading to a sharp 450 basis points contraction in EBITDA margin to 29.3%.
Brokerage firm Macquarie has maintained an 'Outperform' rating on the stock, with a price target of ₹835 per share.
The brokerage said that EBITDA was 11% ahead of its estimates on in-line revenue, while adjusted PAT of ₹150 crore came in 8% below expectations.
Reported net profit included a ₹20 crore gain related to the remeasurement of gratuity obligations, which was more than offset by a ₹25 crore charge linked to employee termination benefits.
The company said that revenue continues to be impacted by lower business from a single large molecule biologics client. Excluding this, the underlying business showed steady momentum.Continue ReadingNote To ReadersDisclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.First Published: Apr 30, 2026 10:07 AM ISTTagsSyngeneSyngene International